XML 123 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Restructuring Plans
 12 Months Ended
Dec. 31, 2019
Restructuring and Related Activities [Abstract]  
Restructuring Plans Restructuring Plans
 
AbbVie continuously evaluates its operations to identify opportunities to optimize its manufacturing and R&D operations, commercial infrastructure and administrative costs and to respond to changes in its business environment. As a result, AbbVie management periodically approves individual restructuring plans to achieve these objectives. In 2019, 2018 and 2017, no such plans were individually significant. Restructuring charges recorded were $234 million in 2019, $70 million in 2018 and $86 million in 2017 and were primarily related to employee severance and contractual obligations. These charges were recorded in cost of products sold, R&D expense and SG&A expenses in the consolidated statements of earnings based on the classification of the affected employees or operations.
The following table summarizes the cash activity in the restructuring reserve for 2019, 2018 and 2017:
(in millions)
 
Accrued balance as of December 31, 2016
$
87

2017 restructuring charges
86

Payments and other adjustments
(87
)
Accrued balance as of December 31, 2017
86

2018 restructuring charges
59

Payments and other adjustments
(46
)
Accrued balance as of December 31, 2018
99

2019 restructuring charges
219

Payments and other adjustments
(178
)
Accrued balance as of December 31, 2019
$
140